Fennec Pharmaceuticals (FENC) Fundamental Analysis: Revenue, Earnings & Valuation

2.32 / 10

Underperform

Fundamentals rate Underperform with a 2.3/10 score. Profit‑MV and Cash‑MV show modest strength, while Asset‑MV, Revenue‑MV and tax ratios are negative. Margins and turnover ratios are mixed, overall indicating weak financial health.

Analysis Checks(5/10)

Revenue-MV

Value-1.29

Score1/3

Weight35.09%

1M Return5.44%

Inventory turnover ratio

Value1.13

Score2/3

Weight-2.58%

1M Return-0.56%

Gross profit margin (%)

Value93.52

Score0/3

Weight-20.41%

1M Return-5.42%

Profit-MV

Value0.41

Score2/3

Weight40.06%

1M Return6.36%

Income tax / Total profit (%)

Value-5.52

Score1/3

Weight0.98%

1M Return0.21%

Current assets turnover ratio

Value0.68

Score1/3

Weight-0.87%

1M Return-0.17%

Fixed assets turnover ratio

Value7899.90

Score3/3

Weight8.49%

1M Return1.76%

Cost of sales ratio (%)

Value6.48

Score2/3

Weight-16.42%

1M Return-3.62%

Asset-MV

Value-0.48

Score0/3

Weight16.43%

1M Return2.73%

Cash-MV

Value-1.97

Score2/3

Weight39.24%

1M Return6.19%

Is FENC undervalued or overvalued?

FENC scores 2.32/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -17.89% net margin, -24.58 P/E ratio, -37.97 P/B ratio, and -550.00% earnings growth, these metrics solidify its Underperform investment rating.